

**University Hospitals Sussex NHS Foundation Trust - Eastern Sites  
Clinical Trials Delivery Performance  
Q1 2021 to 2022**

Royal Sussex County Hospital  
Royal Alexandra Children's Hospital  
Princess Royal Hospital  
Brighon General Hospital  
Sussex Eye Hospital

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/WM/0207	222284	Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation	Range Agreed	10	20	Date Agreed	30/06/2019	10	15/10/2020	10	Withdrawn By Sponsor
19/NE/0374	275170	MK8591A-017 study – A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A (Islatravir/Doravirine) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy.	Range Agreed	1	3	Date Agreed	30/09/2020	4	20/08/2020	4	Recruitment Finished
19/SC/0507	265282	RESPOND EDGE: Repositionable Lotus Edge™ Valve System – Post Market Evaluation of Real World Clinical Outcomes	Range Agreed	10	40	Date Agreed	30/06/2022	39	26/08/2020	39	Recruitment Finished
19/LO/0040	253233	A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE	Number Agreed	5	5	Date Agreed	01/02/2020	1	07/09/2020	1	Recruitment Finished
19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	Number Agreed	2	2	Date Agreed	30/06/2020	0	29/10/2020	0	Withdrawn By Host
18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Range Agreed	1	4	Not Available / Not Agreed			16/11/2020	0	Recruitment Finished
20/YH/0317	288552	Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	330	330	Not Available / Not Agreed			30/01/2021	348	Recruitment Finished